Stock Screener App

Frei -

Installieren

2.07

1.47% 0.03

after-market

Handel nachbörslich: 2.10 0.03 +1.45%

Inflarx Nv (IFRX)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Inflarx Nv Aktie (IFRX) Neueste Nachrichten

Commodore Capital reports 5%+ stake in InflaRx (IFRX) - Stock Titan

InflaRx (IFRX) investors report 15.6% and 12.5% stakes in updated 13G/A - Stock Titan

Sirenia Capital (IFRX) discloses 8.9M InflaRx shares, a 6.1% ownership stake - Stock Titan

InflaRx (IFRX): Farallon group reports 3.33M-share, 2.3% beneficial stake - Stock Titan

EDGAR Filing Documents for 0001140361-26-033149 - SEC.gov

InflaRx N.V. SEC Filing (Aug 13, 2026) - Stock Titan

InflaRx (IFRX) Short Interest & Short Float | Updated Aug 2026 $IFRX - MarketBeat

HC Wainwright Estimates InflaRx's Q3 Earnings (NASDAQ:IFRX) - MarketBeat

InflaRx (NASDAQ:IFRX) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS - marketbeat.com

Cantor Fitzgerald Increases InflaRx (NASDAQ:IFRX) Price Target to $6.00 - MarketBeat

InflaRx N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

FMR LLC and Abigail Johnson (IFRX) disclose 5.5% Inflarx stake in Schedule 13G - Stock Titan

InflaRx NV reports results for the quarter ended June 30Earnings Summary - TradingView

InflaRx N.V. (IFRX) sets up $250M shelf for stock, debt and warrants - Stock Titan

IFRX: Advanced pipeline in AAV and renal diseases, with strong funding and reduced net loss - TradingView

InflaRx Files Mid‑Year 2026 Unaudited Results in SEC Form 6‑K - TipRanks

InflaRx Q2 2026 earnings: Lower costs narrow the operating loss - TradingKey

InflaRx (Nasdaq: IFRX) raises $140m, funds C5a pipeline into 2029 - Stock Titan

InflaRx Reports Q2 2026 Results and Business Update, Advances Izicopan in AAV and Renal Diseases - Quiver Quantitative

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones - Yahoo! Finance Canada

IFRX Q2'26 Earnings: EPS estimate is (0.07) USD - TradingView

Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com

InflaRx NV expected to post a loss of 6 cents a shareEarnings Preview - TradingView

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline - sharewise.com

InflaRx N.V. Revenue Breakdown – NASDAQ:IFRX - TradingView

No Conference Call Planned for InflaRx's Aug. 6 Results - stocktitan.net

IFRX Q2'26 Earnings: revenue estimate is 6.40K USD - TradingView

InflaRx (NASDAQ:IFRX) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat

InflaRx NV (IFRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

InflaRx (NASDAQ:IFRX) Trading Down 2.3%Time to Sell? - MarketBeat

InflaRx NV (IFRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

InflaRx NV (IFRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

InflaRx N.V. Revenue Breakdown – SWB:IF0 - TradingView

InflaRx NV (IFRX) Institutional Confidence - TradingKey

IFRX|InflaRx NV|Price:1.740|Chg%:+0.010 - TradingKey

IFRX|InflaRx NV|Price:1.690|Chg%:-0.050 - TradingKey

TradingKey - TradingKey

InflaRx N.V. Revenue Breakdown – BOATS:IFRX - TradingView

InflaRx NV (IFRX) Cash Flow - TradingKey

InflaRx NV (IFRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

InflaRx (IFRX) Under Pressure as Shares Slip 2.88% Toward Key SupportAlgorithmic Stock Picks - dars.gov.et

IFRX Stock Price, Quote & Chart - ChartMill

InflaRx N.V. (IFRX) Hovers Near Support After Marginal DeclineMA Cross Alert - dars.gov.et

IFRX Q1 2026 Earnings: Narrower-than-Expected Loss on Stability, Stock EasesEarnings Call Q&A - DonanımHaber

InflaRx NV focus on immune therapies as investors weigh long-term prospects - ad-hoc-news.de

InflaRx N.V. (IFRX) Slips 1.79% as Stock Approaches Key Support LevelETF Premium Discount - DonanımHaber

IFRX Q1 2026 Earnings: Surprise EPS Beat Despite Pre-Revenue StatusCapex Guidance - dars.gov.et

Price to earnings forward of InflaRx N.V. – NASDAQ:IFRX - TradingView

IFRXInflaRx NV Revenue Breakdown - Finviz

Price to book forward of InflaRx N.V. – NASDAQ:IFRX - TradingView

InflaRx Moves to Broaden AAV Strategy in Europe After EMA Setback for Tavneos - TipRanks

InflaRx (IFRX) rethinks European AAV path after EMA Tavneos setback - Stock Titan

InflaRx to explore regulatory path for AAV drugs in Europe - Investing.com

InflaRx to explore regulatory path for AAV drugs in Europe By Investing.com - Investing.com South Africa

InflaRx to Engage EMA on Vilobelimab and Izicopan Development Path in AAV - Quiver Quantitative

InflaRx Assessing Feasibility of Broadened Strategy - One News Page

symbol__ Stock Quote Price and Forecast - CNN

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos - The Manila Times

Price to sales forward of InflaRx N.V. – NASDAQ:IFRX - TradingView

Enterprise value to EBITDA forward of InflaRx N.V. – NASDAQ:IFRX - TradingView

Price to earnings forward of InflaRx N.V. – GETTEX:IF0 - TradingView

Price to sales forward of InflaRx N.V. – GETTEX:IF0 - TradingView

Price to book forward of InflaRx N.V. – GETTEX:IF0 - TradingView

Enterprise value to revenue forward of InflaRx N.V. – NASDAQ:IFRX - TradingView

Enterprise value to EBIT forward of InflaRx N.V. – GETTEX:IF0 - TradingView

ETFs Investing in InflaRx N.V. Stocks - TradingView

MRNA

$64.46

1.80%

ROIV

$36.24

0.11%

RPRX

$59.45

1.45%

INSM

$128.32

3.70%

ALNY

$224.60

1.77%

ONC

$362.51

4.33%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters